AR and prostate cancer: Numerous studies have suggested that GTCs hindered prostate cancer progression at various stages of the disease by reducing the expression of the prostate-specific antigen (PSA), the transcriptional activity of the androgen receptor (AR), the activation of chromatin proteins, and DNA methylation of genes [119,120].